checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA sustained improvement in quality of life1

OTEZLA achieves significant and sustained improvement in QoL1

 

IMPROVEMENT IN DLQI TOTAL SCORE UP TO 32 WEEKS1,a,b

otzela quality of life changes in a clinical trial
a

ESTEEM® 1 study. Full analysis set, data as observed. Includes patients with baseline DLQI total score >5.

b

P < 0.001.

BL, baseline; DLQI, dermatology life quality index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; QoL, quality of life.

Reference: 1. Thaçi D, Kimball A, Foley P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31(3):498-506.


Select an e-mail client to share

close x